$SYRE

Spyre Therapeutics prices $403M stock offering at $62/share with 6.5M shares, expected to close April 16, 2026. Prominent underwriters include Goldman Sachs and Jefferies.

Clinical-stage biotech Spyre Therapeutics launches $300M public offering to fund inflammatory bowel disease drug development, with major investment banks leading.

Clinical-stage biotech Spyre Therapeutics announced $300M public offering with $45M underwriter option, led by Jefferies and Goldman Sachs, targeting IBD treatments.

Spyre Therapeutics reports positive Phase 2 results for SPY001 in ulcerative colitis, meeting primary endpoints with significant histopathology improvements and favorable safety.

VR Adviser increased Spyre Therapeutics stake by 1M shares to $120.74M. Stock surged 132% annually, but preclinical risks remain high for retail investors.

Commodore Capital increases Spyre Therapeutics stake to $78.24M as stock surges 63% YoY. Biotech firm has $757M cash and expects Phase 2 data in 2026.